FILTER
FILTERED INTERVIEW RESULTS
Cécile Amory
GENERAL MANAGER, MINING CONTRACTING SERVICES CONGO (MCSC)
Local contracting firm MCSC discusses its strategy for ensuring sustainable growth in the risky DRC mining game.
Rodolphe Kembukuswa
GENERAL MANAGER, BOLLORÉ LOGISTICS DRC
Bolloré DRC believes it has a key role to play in streamlining cargo flows and securing supply and exit corridors for the country.
Malta Forrest
EXECUTIVE VICE PRESIDENT & CEO, GROUPE FORREST
Groupe Forrest is a completely family-owned company that has been operating in the DRC since 1922 without interruption.
Nigel Ferguson
MANAGING DIRECTOR, AVZ MINERALS LIMITED
AVZ Minerals moves forward with its mega-lithium project in the DRC.
Miles Naude
GENERAL MANAGER, MMG
MMG is nearing completion of a feasibility study for the expansion of its Kinsevere mine in the DRC.
Mark Bristow
CEO, BARRICK GOLD CORPORATION
The Barrick Gold merger resulted in the world’s largest gold company – what’s next for its African assets?
Liam Morrissey
CEO, MS RISK
MS Risk identifies, mitigates and reduces security risk to protect client assets around the world and across several sectors.
Peter Ruxton
PRINCIPAL, TEMBO CAPITAL MANAGEMENT
Tembo Capital has 29 years of experience in investing in emerging markets and high-risk mining destinations.
Christophe Fleurence
VICE PRESIDENT, BUSINESS DEVELOPMENT AFRICA, TOTAL EREN
Total Eren develops, finances, invests in, builds and operates renewable energy power plants at a global level.
Denver Dreyer
CEO, WORLEYPARSONS RSA
WorleyParsons is an engineering company that provides project delivery and consulting services to the resources and energy sectors, and complex process industries.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
